Phosphodiesterase Type 5 Inhibitors: Molecular Pharmacology and Interactions with other Phosphodiesterases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|11|31|4047-4058

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.31, 2005-12, pp. : 4047-4058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase Type 5 Inhibitors: Unmet Needs

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3476-3485

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension: A Meta-Analysis

By Jin Bo   Luo Xin-Ping   Ni Huan-Chun   Shi Hai-Ming  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 259-265

Adis International

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Vision Disorders and Phosphodiesterase Type 5 Inhibitors: A Review of the Evidence to Date

By Laties Alan M.  

Drug Safety, Vol. 32, Iss. 1, 2009-01 ,pp. : 1-18

Adis International

Access to resources Recommend Favorite